Research graph
References from Matching-adjusted indirect comparison of zanubrutinib and real-world chemotherapy, rituximab and chemoimmunotherapy in relapsed or refractory marginal zone lymphoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Marginal zone lymphomas: management of nodal, splenic, and MALT NHL
10.1182/asheducation-2008.1.359 · 2008 · External reference
Human marginal zone B cells
10.1146/annurev.immunol.021908.132607 · 2009 · External reference
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
10.1016/j.annonc.2019.10.010 · 2020 · External reference
Unresolved reference
2017 · External reference
Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline
10.1111/bjh.19064 · 2024 · External reference
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023: Featured Updates to the NCCN Guidelines
10.6004/jnccn.2023.0057 · 2023 · External reference
Management of marginal zone lymphomas
10.1182/hematology.2022000362 · 2022 · External reference
The many faces of marginal zone lymphoma
10.1182/asheducation.v2012.1.426.3798535 · 2012 · External reference
Marginal zone lymphoma: state-of-the-art treatment
10.1007/s11864-019-0687-5 · 2019 · External reference
The investigation and management of follicular lymphoma
10.1111/bjh.16872 · 2020 · External reference
Current treatment options in marginal zone lymphoma
2017 · External reference
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment
10.1200/jco.2000.18.17.3135 · 2000 · External reference
The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma
10.1158/1078-0432.ccr-21-1704 · 2021 · External reference
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
10.1182/bloodadvances.2021006083 · 2022 · External reference
Unresolved reference
External reference
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification
10.1200/jco.2013.54.8800 · 2014 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Proportional hazards tests and diagnostics based on weighted residuals
10.1093/biomet/81.3.515 · 1994 · External reference
Martingale-based residuals for survival models
10.1093/biomet/77.1.147 · 1990 · External reference
AUGMENT: a Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma
10.1200/jco.19.00010 · 2019 · External reference
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, Phase III trial
10.1016/s1470-2045(21)00145-5 · 2021 · External reference
Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC)
10.1200/jco.2023.41.16_suppl.e19526 · 2023 · External reference
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
10.1182/bloodadvances.2021005621 · 2022 · External reference
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database
10.3324/haematol.2023.283846 · 2024 · External reference
